Search Results

This partnership reflects our commitment to advancing conversations that directly affect how GPCR research partnership aligns with broader efforts across the life sciences to improve data reproducibility by addressing GPCR supports scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.

GPCRs do not simply flip on or off  but rather function as allosteric proteins, capable of adopting multiple Biased agonism  adds another layer: a pathway bias observed in a recombinant cell line may not hold in Addressing this challenge requires integration of advanced  in vitro  tools with phenotypic screening The methodological advances required to exploit both via multi-pathway functional assays , phenotypic For a more detailed discussion of these concepts and additional expert perspectives from Dr.

Pharmacokinetics—absorption, distribution, metabolism, and excretion—must therefore be addressed early Kenakin often recalls advice from Nobel laureate James Black: Chemists make the drugs.

It prevents discovery teams from advancing compounds based on artifacts of expression systems rather This has advantages: Physiological relevance Functional integration But it obscures pathway-specific

Twist Bioscience's technology addresses inefficiencies and enables cost-effective, rapid, precise, high-throughput the most representative compounds synthesized in C5aR fluorescent ligand development project. * In addition

A strong preclinical signal opens adjacent therapeutic areas. A platform technology reveals additional applications. Every additional program introduces complexity. It consumes leadership attention. This is where biotech fundraising becomes more predictable. ✅ In the end, the advantage is simple but

Kenakin will address receptor theory, assay interpretation, biased signaling, and practical drug discovery s Pharmacology Corner provides a structured environment to maintain interpretive discipline: Weekly advanced If you want structured, year-round access to Terry’s full library — including advanced lectures, archived

The platform is advancing, multiple indications are progressing, a grant application is underway, and When too many priorities advance in parallel, focus starts to diffuse. Resources stretch. When multiple programs advance at the same time, trade-offs become implicit instead of explicit. Every additional initiative competes for the same executive attention, the same scientific bandwidth, Are programs advancing because they are strategically ordered, or because they were never explicitly

Breakthroughs this week: 12th Adhesion GPCR Workshop (Düsseldorf, Sept 16–18, 2026); Free fatty acid These sessions span foundational pharmacology, receptor biology, modeling, translational strategy, and advanced This partnership connects advanced assay and biology capabilities with the scientists and organizations Premium Members also receive a 50%+ discount on Terry’s Corner — unlocking advanced pharmacology depth GPCR Premium — Build Your Structured Advantage ➤

than assays—they build true scientific partnerships that help teams get the most from their data and advance GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.

As datasets expand and systems are tested under new conditions, interpretations often require adjustment What initially appears mechanistically clear can become more nuanced when additional experiments are AMA will take place: Thursday, February 26th at 12:00 PM EST You are invited to submit questions in advance The defining distinction is saturation: Saturation defines the allosteric boundary  — additional modulator Advance promising hits into mechanistic evaluation quickly Use statistics to arbitrate interpretation

Experiments advance. Data improves. Technical milestones are reached. They are strategic signals. 👉 When timelines stop being adjustable. 👉 When costs become hard to unwind assumptions have changed. 👉 They avoid revisiting earlier decisions because reversing them feels like admitting

Upcoming events: 12th Adhesion GPCR Workshop; GPCRnet International Symposium; 5th GPCRs Targeted Drug Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics, efficacy, mechanism, ADME This initiative brings together field experts to advance collective understanding of how GPCR-mediated That means structured, searchable, expert-led training across levels and topics — without additional Premium Members also receive a 50%+ discount on Terry’s Corner , unlocking advanced pharmacology depth

Kenakin highlights the definitive role of patch clamp assays and how high-throughput adaptations have Hepatotoxicity: The Central Organ Challenge The liver, often receiving the highest concentration of orally administered Pharmacokinetic approaches are adapted, sometimes employing exotic carriers or solvents to maximize exposure enhance detection Unique pharmacokinetics may be required for robust toxicology In Silico Toxic Signals Advancements As GPCR science and pharmacological innovation accelerate, timely guidance from foundational to advanced

Rather than chasing potency alone, this session equips drug hunters with system-level thinking: how ADME Optimization is modular  — activity, ADME, and safety can be tuned independently.

Research advances. New initiatives start. Additional questions are explored. The strategic advantage lies in leadership attention, not precision.

When biotech positioning is unclear, founders are forced to adapt their message in every interaction. Over time, this constant adjustment drains confidence and momentum, even when the science is strong. The most damaging effect is subtle. ✅ Founders start adapting their message in real time , trying to The positioning does that work in advance. They respond to questions as they arise, adjusting emphasis depending on who is listening.

Built for growth means building a biotech team that can learn, adapt, and move forward together as the a few keep the company moving forward even when certainty is missing. 👉 They reframe the problem, adjust Do they freeze, escalate, or adapt? Survival-oriented candidates show adjustment, not frustration. 3️⃣ How they define responsibility: Pay They are the ones where individuals can decide, adapt, and move forward without waiting for perfect clarity

Even if the risk is manageable, not addressing it makes the fundraising process harder. other, fundraising conversations move faster and with less friction. ✅ For founders, this creates an advantage

When teams adopt structured decision cycles, consistent narrative checkpoints, and predictable timeline

Academic innovation moves discovery forward only when assays are validated, distributed, and adopted

The expert they admire is right there, but the fear of sounding unprepared wins. a Scientific Career Through Asking Better Questions in Science Late in the conversation, JB offers advice

But you do need a framework for identifying and addressing regulatory gaps early .

Furthermore, image-based data provide an additional check against off-target cytotoxicity or morphological Image-based validation adds interpretive power.   Visual displacement provides an additional confidence layer that traditional homogeneous binding assays

Premium: Sneak Peek Industry insights:  Lilly cuts Zepbound prices; Lilly hits $1T valuation; Novo advances Upcoming events:  Adhesion GPCR Workshop; GRC—Transporters, Ion Channels & GPCRs; MPGPCR Joint Satellite This is where system-level GPCR thinking  becomes a competitive advantage—long before a molecule reaches GPCR is a 501(c)(3) non-profit organization—your participation directly supports our mission to advance

If your pitch doesn’t address timing, portfolio alignment, or internal traction, the audience won’t do Instead of leading with technology, lead with the problem it addresses. ✅ Frame the situation in terms

The sections below synthesize the key topics addressed during the AMA and highlight the GPCR pharmacology Biased agonism introduces additional layers where one pathway may mimic “reflex-like” counterbalancing Kenakin  emphasized that the key advantage is not subtlety for its own sake—it’s bounded pharmacology For complex GPCR systems, this boundary is a strategic advantage: NAMs can only shift an agonist curve Kenakin  highlighted historical β-adrenergic cases where tachycardia appeared only once compounds reached

It started with curiosity, openness, and the humility to admit that better answers required better tools It fused them, creating a hybrid view of receptor signaling that has now been adopted by labs worldwide

visualize receptor localization, internalization kinetics, and ligand interactions in intact cells offers advantages Key scientific advantages include: Physiological Relevance Fluorescent ligand binding occurs in intact Looking ahead, combining HCS with advanced probe design, scalable analytics, and expert scientific support

Which neurons respond Which cell populations drive therapeutic benefit Where not  to target to avoid adverse